Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MYOC | Q99972 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19147744 | 0.89 | LPAR1 (0.43) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6939617 | 0.84 | KMT2A (0.60) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6939392 | 0.83 | MEN1 (0.79) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6941251 | 0.81 | KMT2A (0.59) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6937560 | 0.81 | MEN1 (0.59) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL4236718 | 0.80 | MEN1 (0.64) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6936821 | 0.79 | MEN1 (0.68) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL11768264 | 0.78 | MEN1 (0.69) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL11806188 | 0.77 | MEN1 (0.72) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL6943802 | 0.77 | MEN1 (0.68) | MEN1KMT2AMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | claimed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | claimed |
| US-20220090023-A1 | METHODS FOR REGULATING POTENCY OF PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF | ACADEMIA SINICA (TW) | 2022-03-24 | — | — | US | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| CN-114652816-B | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | 生物组织控股公司 | 2025-03-14 | — | — | CN | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20230279048-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2023-09-07 | — | — | US | disclosed |
| US-20230132366-A9 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | DENALI THERAPEUTICS INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20230000917-A1 | TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | UCL BUSINESS LTD (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2010124296-A2 | COMPOSITIONS CONTAINING HC•HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010065491-A2 | METHODS OF TREATING INFLAMMATORY DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010042548-A2 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100093636-A1 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009117710-A2 | METHODS OF TREATING INFLAMMATION | CAROLUS THERAPEUTICS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | MEN1 944/4885KMT2A 93/4885MAPT 584/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | MEN1 2399/4885KMT2A 686/4885MAPT 792/4885 |
| US-20100183598-A1 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | TNNI3, TNNT2, FABP3 | MEN1 4609/4885KMT2A 1019/4885MAPT 3170/4885 |
| US-20220090023-A1 | METHODS FOR REGULATING POTENCY OF PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF | CDYL, ZFX, CDYL2 | MEN1 4506/4885KMT2A 3395/4885MAPT 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.